Table 1.
Blood pressure reductions with RDN in recently completed sham-controlled trials
| SPYRAL HTN-OFF MED | SPYRAL HTN ON-MED | RADIANCE-HTN SOLO | REDUCE HTN: REINFORCE | |
|---|---|---|---|---|
| Follow-up data published | 3 months | 6 months | 6 months | 6 months |
| Sham-control | Yes | Yes | Yes | Yes |
| Adherence measurements | Yes | Yes | No | No |
| Feasibility/powered | Feasibility | Feasibility | Powered, primary endpoint (2 months) met | Powered, primary endpoint (2 months) not met |
| Patients randomized | 80 | 80 | 146 | 51 |
| Difference in BP RDN vs. sham (mmHg) | ||||
| 24-h SBP | −5.0 | −7.0 | −4.1 | −7.2 |
| P-value | 0.041 | 0.006 | 0.006 | 0.083 |
| 24-hr DBP | −4.4 | −4.3 | −1.8 | −3.6 |
| P-value | 0.002 | 0.017 | 0.07 | 0.172 |
| Daytime SBP | −5.4 | −6.1 | −6.3 | −9.7 |
| P-value | 0.057 | 0.018 | <0.001 | 0.021 |
| Daytime DBP | −3.9 | −4.1 | −2.6 | |
| P-value | 0.039 | 0.03 | 0.01 | |
| Office SBP | −7.7 | −6.6 | −6.5 | −11.4 |
| P-value | 0.016 | 0.025 | 0.007 | 0.006 |
| Office DBP | −4.9 | −4.2 | −4.1 | −5.4 |
| P-value | 0.008 | 0.02 | 0.005 | 0.037 |